Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) Director Ra Capital Management, L.P. purchased 1,200,000 shares of Janux Therapeutics stock in a transaction on Friday, October 18th. The stock was bought at an average price of $44.75 per share, for a total transaction of $53,700,000.00. Following the transaction, the director now directly owns 9,317,246 shares in the company, valued at approximately $416,946,758.50. The trade was a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Janux Therapeutics Stock Performance
Shares of Janux Therapeutics stock opened at $53.31 on Friday. The stock has a market capitalization of $2.76 billion, a PE ratio of -43.54 and a beta of 3.54. Janux Therapeutics, Inc. has a 52 week low of $5.65 and a 52 week high of $65.60. The stock has a 50 day moving average price of $46.62 and a two-hundred day moving average price of $45.79.
Janux Therapeutics (NASDAQ:JANX – Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.20. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The business had revenue of $8.90 million during the quarter, compared to analyst estimates of $0.77 million. The business’s revenue for the quarter was up 709.1% compared to the same quarter last year. Research analysts forecast that Janux Therapeutics, Inc. will post -1.18 EPS for the current year.
Institutional Investors Weigh In On Janux Therapeutics
Wall Street Analyst Weigh In
JANX has been the topic of several analyst reports. Stifel Nicolaus started coverage on Janux Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $70.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Janux Therapeutics in a research note on Monday, August 19th. Cantor Fitzgerald reissued an “overweight” rating and set a $100.00 target price on shares of Janux Therapeutics in a research note on Monday, September 16th. UBS Group initiated coverage on shares of Janux Therapeutics in a research report on Thursday. They set a “buy” rating and a $69.00 price target on the stock. Finally, Wedbush reissued an “outperform” rating and issued a $74.00 price objective on shares of Janux Therapeutics in a research report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $66.44.
View Our Latest Stock Analysis on Janux Therapeutics
About Janux Therapeutics
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Featured Stories
- Five stocks we like better than Janux Therapeutics
- Consumer Staples Stocks, Explained
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- The Risks of Owning Bonds
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- How to Calculate Options Profits
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.